"It’s been in the dumps for no strong apparent reason."
In those early days orphan drugs weren't worth much. That's now changed in a big way. Drugs with orphan drug designation are worth heaps, and it's a hot area.
"Biopharmaceutical companies are attracted to the orphan-drug market, because it can be very lucrative. Around 30 million Americans suffer from 7,000 or so rare diseases. Market research firm EvaluatePharma projects that worldwide orphan-drug sales will top $200 billion by 2022."
https://www.********/investing/2018/02/03/3-top-orphan-drug-stocks-to-buy-now.aspx
75-80% chance of a deal here., page-6
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.64 |
Change
-0.100(5.76%) |
Mkt cap ! $278.5M | |||
| Open | High | Low | Value | Volume |
| $1.71 | $1.71 | $1.64 | $205.3K | 123.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1526 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 234 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |